FindTrial
Sign In

Feasibility and mechanism of autologous blood transfusion after ozone treatment in liver cancer surgery

Feasibility and mechanism of autologous blood transfusion after ozone treatment in liver cancer surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084100
Enrollment
Unknown
Registered
2024-05-10
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer disease

Interventions

experimental group:Ozone treatment with white blood cell filter infusion
control group:Ozone treatment
control group 2:Routine surgical area bleeding

Sponsors

The Fourth Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 ~ 60 years old; 2. Patients who intend to undergo liver cancer surgery under general anesthesia on an elective basis.

Exclusion criteria

Exclusion criteria: 1. Patients who are participating in other clinical trials; 2. Patients with pre-existing liver cancer metastases; 3.ASA >=III

Design outcomes

Primary

MeasureTime frame
CTCs;CEA;CA19-9;CA125;plakoglobin;—

Secondary

MeasureTime frame
IL-6;IL-7;HCT;MCV;MCH;MCHC;RDW;—

Countries

China

Contacts

Public ContactTian Ayong

The Fourth Affiliated Hospital of China Medical University

tianayong@126.com+86 139 4018 2455

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026